Research Article
Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas
Table 2
Noninvasion group versus invasion group and nonrecurrent group versus primary recurrent group.
| | | Noninvasion | Invasion | X2 | P | Nonrecurrence | Primary recurrence | X2 | P |
| NR2C2 | Low- | 26(63.4%) | 6(31.6%) | 5.287 | 0.021 | 32(53.3%) | 13(30.2%) | 5.433 | 0.020 | | High- | 15(36.6%) | 13(68.4%) | | | 28(46.7%) | 30(69.8%) | | | BTG2 | Low- | 35(85.4%) | 18(94.7%) | 0.384 | 0.536 | 53(88.3%) | 43(100%) | 3.698 | 0.054 | | High- | 6(14.6%) | 1(5.3%) | | | 7(11.7%) | 0(0%) | | | CDK2 | Low- | 1(2.4%) | 1(5.3%) | - | 0.537 | 2(3.3%) | 11(25.6%) | 11.242 | 0.001 | | High- | 40(97.6%) | 18(94.7%) | | | 58(96.7%) | 32(74.4%) | | | TBX19 | Low- | 31(75.6%) | 11(57.9%) | 1.940 | 0.164 | 42(70.0%) | 38(88.4%) | 4.875 | 0.027 | | High- | 10(24.4%) | 8(42.1%) | | | 18(30.0%) | 5(11.6%) | | |
|
|